Navigation Links
ConjuChem to evaluate strategic alternatives
Date:1/19/2010

MONTRÉAL, Jan. 19 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies, Inc. (TSX: CJB) announced today that it has established a Special Committee of independent Board members to explore and evaluate all strategic alternatives including, but not limited to, a sale of the Company or the sale of all or a substantial part of its assets. The Committee will be working with management and external consultants to expeditiously make recommendations as to the optimal path forward for ConjuChem and all its stakeholders. The Committee will be chaired by Jacques Lapointe, Chairman of the Board, and include Steve Perrone and William Heiden.

At this time, ConjuChem has not made a decision to pursue any specific strategic transaction or other strategic alternative but there is an expectation that this process will result in a transaction or other strategic alternative being implemented. ConjuChem does not intend to comment further on this process unless and until its Board of Directors has approved a specific transaction or other strategic alternative.

About ConjuChem

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide.

The Company has two major development programs: PC-DAC(TM):Exendin-4, a GLP-1 agonist in Phase II for the treatment of Type II diabetes and PC-Insulin, a long-acting basal insulin in preclinical testing.

Detailed descriptions of the Company and its technologies can be viewed on the Company's website

SOURCE ConjuChem Biotechnologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ConjuChem Provides Development Update
2. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
3. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
4. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
5. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
6. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
10. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
11. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... and EMERYVILLE, Calif., May 14 Bayer HealthCare Pharmaceuticals, ... ) today announced that more than 65 studies evaluating ... at the 2009 American Society of Clinical Oncology (ASCO) ... cancers - in the treatment of unresectable hepatocellular carcinoma ...
... and Phase 1 safety studies, and plans for Phase ... (BPH) are to be presentedCINCINNATI, May 14 Ausio ... for an aging global population, will lead off the ... 2009 at 9:00 AM in Atlanta, Georgia. Ausio has ...
... Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... 2 clinical trial of its lead drug, VIA-2291 in ...
Cached Biology Technology:Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 6Ausio Pharmaceuticals to Present at Bio(R) 2009 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:4/23/2014)... 2 million Food Standards Agency (FSA) project to map ... workers. , Norovirus outbreaks can rapidly affect large ... frozen strawberries infected 11,000 people in Germany, but there ... strains cause infection and which foods are the most ... will produce data that will help the FSA to ...
(Date:4/22/2014)... will lead a five-year, $3 million study to determine ... the transport of dissolved organic matter (DOM) through the ... the chemical composition and water quality of the watershed ... National Science Foundation,s MacroSystems Biology program, researchers will collect ... begins in Canada and runs through five U.S. states, ...
(Date:4/22/2014)... Calif. Inspired by the fist-like club of ... University of California, Riverside, in collaboration with University of ... structure for composite materials that is more impact resistant ... "The more we study the club of this tiny ... so many things we use every day," said David ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... the body of pathogens. As important as resisting infection, is ... toxins produced by pathogens or by components of the host ... damage inflicted to different tissues and organs that, if uncontrolled, ... , The in-built capacity that an infected individual has ...
... LANSING, Mich. In the current issue of Science ... virus evolves, which sheds light on how easy it can ... showed for the first time how the virus called "Lambda" ... an innovation that took four mutations to accomplish. This virus ...
... magician employing sleight of hand, the protein mitoNEET -- a ... draws the eye with a flurry of movement in one ... else. Using a combination of laboratory experiments and computer ... San Diego (UCSD) have deciphered part of mitoNEET,s movements to ...
Cached Biology News:European Research Council supports search for regulators of tissue damage 2MSU researchers show how new viruses evolve, and in some cases, become deadly 2Rice, UCSD scientists probe form, function of mysterious protein 2Rice, UCSD scientists probe form, function of mysterious protein 3
... assay kit designed to detect poly(ADP-ribose) polymerase ... an enzyme implicated in DNA damage and ... by caspase-3. Cleavage of PARP from the ... a hallmark of apoptosis. Each kit is ...
... comes with a shutter (controlled via a TTL ... The DH-2000 Deuterium Tungsten Halogen Light ... tungsten halogen light sources in a single optical ... stable output from 215-200 nm. In addition, deep-UV ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... Nematode microRNA Microarray contains all known ...
Biology Products: